NICE 'minded to say no' to MabThera PharmaTimes NICE has been examining MabThera (rituximab)'s use in its licensed indication for inducing remission, in combination with glucocorticoids, in adults with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, an inflammatory autoimmune ... |
